Chau Quang Khuong

CIK 1609405 · last filed 2023-06-23

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.51M

Companies

8

Total Filings

70

Lifetime Open-Market Net

-$141.53M

Filer Profile

Reported Address
C/O ORBIMED ADVISORS
601 LEXINGTON AVENUE, 54TH FLOOR
NEW YORK, NY 10022
Related Filers
PALVELLA THERAPEUTICS, INC. — 13 joint filings, latest 2017-10-27
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NXTC Director 196,751 $7.00 $1.38M $5.25M 6 2023-06-23
Damora Therapeutics, Inc. (GLTO) Delisted Director 41,272 $28.69 $1.18M $11.00M 5 2023-06-15
Fusion Pharmaceuticals Inc. (FUSN) Delisted Director 234,193 $21.55 $5.05M $15.27M 6 2023-06-14
SYNLOGIC, INC. (SYBX) Delisted Director 246,444 $0.69 $170.0K $0 7 2021-04-22
INSP Director 1,875 $73.00 $136.9K -$168.53M 21 2020-10-13
Whitehawk Therapeutics, Inc. (ARPO) Delisted Director 346,263 $33.00 $11.43M $2.99M 2 2019-06-19
PALVELLA THERAPEUTICS, INC. (PIRS) Delisted Director 89,928 $13.60 $1.22M $1.38M 12 2017-10-27
OTONOMY, INC. (OTIC) Delisted Director 1,850,684 $0.08 $142.5K -$8.89M 6 2016-06-21

Recent Filings · Page 3 of 7

70 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-07-02 Fusion Pharmaceuticals Inc. (FUSN) Delisted Mixed +3,122,770 $15.27M EDGAR
2020-06-30 Fusion Pharmaceuticals Inc. (FUSN) Delisted Mixed $0 EDGAR
2020-06-15 NXTC Grant (A) $0 EDGAR
2020-06-08 SYNLOGIC, INC. (SYBX) Delisted Grant (A) $0 EDGAR
2020-05-04 INSP Grant (A) $0 EDGAR
2020-04-14 INSP Grant (A) +183 $0 EDGAR
2020-03-10 INSP Sell (S) −500,000 -$41.76M EDGAR
2020-03-05 INSP Sell (S) −500,000 -$42.12M EDGAR
2020-01-14 INSP Grant (A) +147 $11.9K EDGAR
2019-11-29 INSP Sell (S) −124,000 -$8.77M EDGAR
Showing 2130 of 70
Page 3 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.